Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease-Reference-Cited by-同舟云学术

Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease

Published:2022-07-26 Issue:8 Volume:1 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Buhl Sine¹,Steenholdt Casper¹,Brynskov Jørn¹,Christensen Katrine Risager¹,Dorn-Rasmussen Maria¹,Thomsen Ole Østergaard¹,Bendtzen Klaus²,Klausen Tobias Wirenfeldt¹,Dahlerup Jens Frederik³,Thorsgaard Niels⁴,Jahnsen Jørgen⁵,Molazahi Akbar⁶,Pedersen Natalia⁷,Kjeldsen Jens⁸,Almer Sven⁹¹⁰,Dahl Eva Efsen¹¹,Vind Ida¹²,Cannon Annett Gerhardt¹³,Marsal Jan¹⁴,Sipponen Taina¹⁵,Agnholt Jørgen Steen³,Kievit Hendrika Adriana Linda⁴,Aure Synnøve Louise⁵,Martinsen Lars⁶,Meisner Svetlana⁷,Hansen Jane Møller⁸,Ainsworth Mark Andrew¹⁸

Affiliation:

1. Department of Gastroenterology, Copenhagen University Hospital–Herlev and Gentofte, Herlev, Denmark

2. Institute for Inflammation Research IRR, Rigshospitalet University Hospital, Copenhagen

3. Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark

4. Department of Medical Diseases, Herning Regional Hospital, Herning, Denmark

5. Department of Gastroenterology, Akershus University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo

6. Department of Medical Diseases, Nykøbing F. Regional Hospital, Nykøbing, Denmark

7. Department of Gastroenterology, Slagelse Regional Hospital, Slagelse, Denmark

8. Department of Medical Gastroenterology S, Odense University Hospital, Odense, Denmark

9. Inflammatory Bowel Disease Unit, Division of Gastroenterology, Karolinska University Hospital, Stockholm, Sweden

10. Departement of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

11. Department of Gastroenterology K, Copenhagen University Hospital–Bispebjerg, Frederiksberg, Denmark

12. Department of Gastroenterology, Copenhagen University Hospital–Amager and Hvidovre, Hvidovre, Denmark

13. Diagnostic Center, Silkeborg Regional Hospital, Central Jutland, Denmark

14. Department of Gastroenterology, Skåne University Hospital, Malmö, Sweden

15. Gastroenterology, Abdominal Center, Helsinki University Hospital, University of Helsinki, Helsinki

Publisher

Massachusetts Medical Society

Reference23 articles.

1. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials

2. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

3. Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials

4. Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III)

5. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate)

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis;Clinical Gastroenterology and Hepatology;2024-01

2. De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice;Gastroenterología y Hepatología;2023-08

3. Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors;World Journal of Clinical Cases;2023-04-26

4. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology;Digestive and Liver Disease;2023-04

5. Serum Immune Profiling in Paediatric Crohn’s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments;Journal of Crohn's and Colitis;2023-03-19